Mounjaro Not Working For Me — Reasons, Reality Checks and Next Steps

The biggest misconception: 'not working yet' is not the same as 'not working'

A question our prescribers hear most weeks is some version of: "I'm two or three weeks in and I've barely lost anything, is this medicine doing anything at all?" The honest answer is that, at this stage, it probably is doing something, just not the thing you are looking for yet.

Tirzepatide starts at 2.5mg because that dose gives your gut and your metabolism time to adjust. It was never intended to drive significant weight loss on its own; the job of that first pen is adjustment. Many people notice appetite changes early, but the scale often lags behind. Expecting rapid loss in week two sets up a comparison the medicine was never designed to win.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, ran for 72 weeks, because meaningful, sustained weight loss takes that kind of time. The participants who reached around 20% average body-weight reduction at 15mg did not get there in a month. They got there through a stepped titration and consistent adherence over more than a year. If you are not yet at your maintenance dose, the comparison point is not "why am I not losing like the trial?" but "am I on the right trajectory?"

You can read more about expected timelines on our page covering how long Mounjaro takes to work.

Real reasons progress can slow, and which ones are fixable

When Mounjaro is genuinely not delivering results, the culprits usually fall into one of a few categories. None of them mean the medicine is inherently wrong for you.

Dose: If you are still at 2.5mg or 5mg and weight loss has stalled, the dose may simply not be suppressing your appetite enough yet. Titration exists for exactly this reason. This is a clinical conversation, not a self-managed one.

Eating pattern: Tirzepatide reduces appetite dramatically in many people, but it does not override all food choices. High-calorie liquid foods (smoothies, alcohol, full-fat lattes) pass through the stomach quickly and do not trigger the same fullness signal that solid food does. Some people find they eat less at meals but graze more, effectively replacing what the medicine removed.

Injection technique: Air bubbles, injecting into scar tissue, or not rotating sites can reduce how much medicine is actually absorbed. The Patient Information Leaflet and your prescriber are the authoritative reference here.

Underlying factors: Poor sleep, high chronic stress and certain medications can all work against appetite regulation, regardless of what tirzepatide is doing. These are worth raising in a clinical review.

Our dedicated page on Mounjaro not working for weight loss goes deeper into each of these variables.

Plateaus are not failure, but three months of no movement deserves a look

Weight loss is rarely linear. After an initial period of faster progress, most people hit a stretch where the scale barely moves. This is partly a metabolic adaptation and partly a normal feature of how tirzepatide works in the body. It does not mean the medicine has stopped working; it often means your body has found a new equilibrium at this dose.

The question is how long the plateau has lasted. A few weeks of no movement, especially if clothes still fit differently or you feel less hungry, is not a red flag. Three months of no movement at the highest dose you have been on is worth discussing with a prescriber. NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed if weight loss is less than 5% after six months at the highest tolerated dose, that is the clinical threshold, not a few slow weeks.

If you are approaching or past that marker, our page on not losing weight on Mounjaro after three months may help you frame that conversation with your prescriber. You might also find it useful to read about the specific reasons tirzepatide may not be working, or explore what the options are if Mounjaro is not working.

When to escalate, and what escalation actually looks like

Stopping Mounjaro because it feels slow is almost always premature. Switching to a different treatment entirely is sometimes the right answer, but only after a proper assessment. The realistic options, depending on your clinical picture, include: continuing at the current dose for longer, titrating to the next strength, reviewing lifestyle factors alongside the medicine, or (in a small number of cases) considering an alternative approach entirely.

None of those decisions should be made unilaterally. Tirzepatide is a prescription-only medicine, and changes to treatment need a prescriber's review, not a forum recommendation. If you want to think through the wider picture of how Mounjaro works and what it is designed to do, that context can help you go into a clinical conversation better prepared.

For a broader look at your options, our free consultation connects you with a GPhC-registered prescriber who can review your current treatment and assess what makes clinical sense for you specifically. There is no obligation and no subscription.